Loxonin Arrived in the Family Medicine Cabinet in 2011. Where Was It for the 25 Years Before That?

The second installment of Phase 1. This time, the medicine cabinet.

When you open a Japanese household's medicine cabinet today and find a box of Loxonin S sitting there, that ordinary scene is something that has only existed since January 21, 2011. Fewer than 15 years.

The prescription version — "Loxonin" — has existed since 1986. So during the 25 years in between, where exactly was this drug, and what was holding it up? Let's go to the primary sources.

The Punchline

The over-the-counter Loxonin S was launched by Daiichi Sankyo Healthcare on January 21, 2011. It had been approved by the Ministry of Health, Labour and Welfare a full year earlier — on January 22, 2010 — as a "Switch-OTC" drug. It was the first analgesic switched-OTC in Japan since ibuprofen in 1985, a gap of 26 years.

Primary sources:

• Daiichi Sankyo Healthcare, "First-of-its-kind OTC analgesic Loxonin S, containing the medical-grade ingredient loxoprofen sodium hydrate" (press release, January 17, 2011)
• Yakuji Nippo, "MHLW approves three ingredients including Loxoprofen as Switch-OTC" (January 22, 2010)
• Yakuji Nippo, "Daiichi Sankyo Healthcare launches Switch-OTC analgesic Loxonin S" (January 21, 2011)
• Daiichi Sankyo Healthcare, official "History of Loxonin"
• MHLW Pharmaceutical Affairs and Food Sanitation Council, OTC Drugs Subcommittee minutes (November 2009)

1. 1986: The Day Prescription Loxonin Was Born

Loxoprofen sodium hydrate was a compound that Sankyo Co., Ltd. (now part of Daiichi Sankyo) began clinical trials on in 1980. In July 1986, it was approved and launched as the prescription drug Loxonin (tablets and granules).

Two design choices stood out.

The first is that loxoprofen is a prodrug. When you swallow the tablet, the molecule is not pharmacologically active yet — it is absorbed through the GI tract and only then converted to its active metabolite in the body. Because of this, it irritates the gastric mucosa less directly than other NSAIDs, giving it a clinically meaningful edge in GI tolerability.

The second is fast onset. Time-to-peak plasma concentration is short, which makes it well-suited to the kinds of pain people want to act on quickly: headaches, menstrual pain, dental pain.

Both of these properties would, twenty-five years later, become the case for letting the public buy this drug without a prescription.

2. The Primary Source: November 2009 Council Minutes and the January 22, 2010 Approval

The work to switch loxoprofen from prescription-only to over-the-counter began in earnest in 2009.

In November 2009, the OTC Drugs Subcommittee of the Pharmaceutical Affairs and Food Sanitation Council (MHLW) put three active ingredients on the same agenda for switch-OTC review:

During this review, the Japanese Orthopaedic Association formally requested that pharmacist-mediated counseling be made strict, since persistent pain can mask underlying conditions like osteoarthritis or rheumatoid arthritis that should be diagnosed, not self-medicated.

On January 22, 2010, MHLW approved switch-OTC status for all three ingredients. More than ten products across multiple manufacturers — Loxonin S (Daiichi Sankyo Healthcare), Alesion 10 (SS Pharmaceutical), Selbelle (Sato Pharmaceutical), and others — received approval the same day. All three were classified as Class 1 OTC drugs, the strictest tier, requiring face-to-face sale by a pharmacist with written information provision.

3. The One-Year Gap Between Approval and Launch

There is a one-year gap.

• January 22, 2010: Approval (MHLW)
• January 21, 2011: Launch (Daiichi Sankyo Healthcare)

What happened during that year? When I had Claude cross-read Daiichi Sankyo Healthcare's January 17, 2011 press release with the corresponding trade-press coverage, the "preparation list" became clear:

• Building the Class 1 sales infrastructure: pharmacist-staffed stores, written information templates, point-of-sale explanation tools
• Rewriting the package insert for OTC use (the OTC dosing, warnings, and age restrictions are not the same as the prescription version)
• Final packaging design and product naming — to avoid confusion with the prescription product, the OTC version is named "Loxonin S", not just "Loxonin"
• Distribution: shifting from prescription wholesale channels to drugstore-bound channels

In other words, that year was the time it takes to translate "approved by the regulator" into "on a drugstore shelf you can actually buy." Approval is not the same as launch — that obvious fact is part of the distance between drug regulation and the consumer.

4. What Has Changed: 26 Years of Silence, and What Came After

In the official launch release, Daiichi Sankyo Healthcare deliberately put one sentence in bold:

The switch-OTC of an analgesic active ingredient is the first since ibuprofen in 1985 — a 26-year gap.

A generation. What changed in this market over those 26 years?

The most easily missed line is the August 25, 2020 downgrade of topical Loxonin S to Class 2. Loxonin S Tape, Pap, Gel and similar topical products were reclassified from Class 1 to Class 2 on that date, after roughly three years of post-marketing surveillance had shown serious adverse events to be within the expected range.

In other words, a switch-OTC's class is not fixed — it can step down based on real-world safety data. The contents of the medicine cabinet are quietly tracking changes in regulatory state.

5. The 25-Year Wall: Why "Rx → OTC" Takes So Long

For loxoprofen, the prescription approval (1986) to OTC approval (2010) took 24 years, and prescription to OTC launch took 25 years. When I asked Claude to break down the structure of this delay, three drivers emerged.

Driver 1: You need accumulated post-marketing safety data on the prescription side.

The basic precondition for a Switch-OTC in Japan is that the active ingredient has been used as a prescription drug for some period and that adverse-event information has accumulated. The customary lower bound is about 10 years, but it is only a floor: usage under physician supervision and self-medication under pharmacist counseling have different risk profiles. Heavily-used analgesics generally need much more than 10 years of data.

Driver 2: The pharmaceutical retail system itself was being redesigned (2006–2009).

Right before the 2009 deliberation on loxoprofen's switch-OTC, the entire framework of pharmaceutical retail in Japan was being rewritten:

• June 2006: Revised Pharmaceutical Affairs Law enacted
• June 2009: Brought into force (introducing the Class 1/2/3 distinction and the registered seller system)

So loxoprofen's OTC launch was timed to ride on top of the new system, as the flagship Class 1 product. Loxonin S becoming the standard-bearer for "Class 1" helped give that regulatory category its public identity, and vice versa.

Driver 3: The shadow of the 1962 thalidomide tragedy.

This is more about regulatory culture than regulation. In 1962, the (then) Ministry of Health and Welfare approved thalidomide after less than two hours of review, with catastrophic consequences. That history baked a "tilt cautious" stance into every subsequent piece of Japanese pharmaceutical administration. Switch-OTC review is not exempt — high-visibility ingredients get extra time.

When approvals feel slow, that slowness is partly the cost of a system that learned from past harm. It is not a coincidence that Japan's OTC market since the 1980s has not produced another thalidomide-scale disaster.

6. What This Lets You Read on the Box: Three Practical Takeaways

In the Phase 1 format, the ending returns from primary sources to the medicine cabinet.

Takeaway 1: The meaning of Class 1 / 2 / 3 is written in the council minutes.

When a Japanese drugstore says "please ask the pharmacist before purchasing Loxonin S," that is the Class 1 rule from the June 2009 revised Pharmaceutical Affairs Law. Newly switched-OTC ingredients (loxoprofen) and ingredients requiring active risk management (Riup / minoxidil) are placed in Class 1.

Class 2 may be sold by a pharmacist or a registered seller, Class 3 has the lightest restriction. The same active ingredient can step down through these tiers as post-marketing safety data accumulates. The Loxonin S topical line did exactly that in August 2020.

Takeaway 2: Same active ingredient, but the Rx and OTC labels are not the same.

Loxonin (Rx) and Loxonin S (OTC) share an active ingredient, but the package inserts diverge:

"Same active ingredient, therefore I can take it the same way" is a misread. The OTC version is conservatively designed for self-administered use without physician oversight.

Takeaway 3: Knowing the OTC year tells you the drug's generation.

Pick up any drug at home and ask: "Since when has this been over the counter?" That single question reveals which generation a drug belongs to.

• OTC since before 1985: aspirin, acetaminophen, ibuprofen (classical analgesics)
• OTC since 2011: loxoprofen (Class 1 switch-OTC)
• OTC since 2014: some second-generation antihistamines like fexofenadine
• Reclassified after 2020: topical H2 blockers and similar items moved to Class 2

"OTC year" reflects both drug history and regulatory history at once.

7. Application: Pick One Box, Dig One Source

In the standard Phase 1 format, three applications.

Application 1: Pick one drug from your medicine cabinet.

Loxonin S, Gaster 10, Alesion 20, Riup, Halcion — anything is fine. The package side or the package insert always carries the manufacturer/distributor name and the path to the approval year.

Application 2: Look up the OTC approval year for that one drug.

Gaster 10 (an H2 blocker) was switched-OTC in 1997. Riup (minoxidil) was switched-OTC in 1999. One minute on the internet is enough. Knowing the "since when OTC" year, drug by drug, makes the medicine cabinet stratify itself before your eyes.

Application 3: Notice the Class 1 / 2 / 3 layout in the store.

In Japanese drugstores, Class 1 lives behind the pharmacy counter, Class 2 and Class 3 on the open shelves. That layout encodes which generation of the regulatory framework each drug sits on.

Pick a refrigerator condiment and dig one source. Pick a medicine cabinet drug and dig one source. That is the Pharma Archaeology format.

8. Sources

• Daiichi Sankyo Healthcare, press release "First-of-its-kind OTC analgesic Loxonin S containing the medical-grade ingredient loxoprofen sodium hydrate" (January 17, 2011): daiichisankyo-hc.co.jp/content/000023387.pdf
• Daiichi Sankyo Healthcare, "History of Loxonin" (official): daiichisankyo-hc.co.jp/site_loxonin-s/history
• Daiichi Sankyo Healthcare, ingredient page for loxoprofen sodium hydrate: daiichisankyo-hc.co.jp/rd/ingredient/loxoprofen-sodium
• Yakuji Nippo, "MHLW approves three ingredients including Loxoprofen as Switch-OTC" (January 22, 2010): yakuji.co.jp/entry17929.html
• Yakuji Nippo, "Daiichi Sankyo Healthcare launches Switch-OTC analgesic Loxonin S" (January 21, 2011): yakuji.co.jp/entry21687.html
• Eparku-no-Madoguchi, "[August 25, 2020] Loxonin S topical line moves to Class 2": kusurinomadoguchi.com/column/articles/loxonin-otc-news
• Pharmaceutical and Medical Device Regulatory Science Foundation, "The thalidomide affair and the origins of Japanese pharmaceutical administration": pmrj.jp/publications/02/shiryo_slides/yakugai_shiryo_sengo.pdf
• MHLW Pharmaceutical Affairs and Food Sanitation Council, OTC Drugs Subcommittee minutes (November 2009)

This series is an archival exercise on past documents. Modern decisions about medicine and health must be based on current sources and on the advice of physicians and pharmacists, taken under the reader's own responsibility. This article does not endorse the use of any specific drug.

→ The complete prompt set used in the first seven episodes is consolidated in Episode 7 (Templates) and the first edition of the book.